Sio Gene Therapies Inc. (SIOX) SEC Filing 8-K Material Event for the period ending Wednesday, January 19, 2022

Sio Gene Therapies Inc.

CIK: 1636050 Ticker: SIOX

View differences made from one to another to evaluate Sio Gene Therapies Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Sio Gene Therapies Inc..


Assess how Sio Gene Therapies Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Sio Gene Therapies Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Ticker: SIOX
CIK: 1636050
Form Type: 8-K Corporate News
Accession Number: 0001636050-22-000002
Submitted to the SEC: Tue Jan 25 2022 4:50:34 PM EST
Accepted by the SEC: Tue Jan 25 2022
Period: Wednesday, January 19, 2022
Industry: Pharmaceutical Preparations
  1. Event for Officers

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: